Eular guidelines

In view of substantial new evidence, an update was conducted with the aim of producing CVD risk management recommendations for patients with IJD that now incorporates an increasing evidence base. A multidisciplinary steering committee representing 13 European countries comprised 26 members including patient representatives, rheumatologists, cardiologists, internists, epidemiologists, a health professional and fellows. Systematic literature searches were performed and evidence was categorised according to standard guidelines.

The evidence was discussed and summarised by the experts in the course of a consensus finding and voting process. Three overarching principles were defined.

Eular guidelines, ‪Attila Hamar‬ - ‪Google Scholar‬ - Eular guidelines

First, there is a higher risk for CVD in patients with RA, and this may also apply to ankylosing spondylitis and psoriatic arthritis. Third, the use of non-steroidal anti-inflammatory drugs and corticosteroids should be in accordance with treatment-specific recommendations from EULAR and Assessment of Spondyloarthritis International Society.

Ten recommendations were defined, of which one is new and six were changed compared with the eular guidelines. Each designated an appropriate evidence support level.

This underscores the need for CVD risk management in eular guidelines patients. These recommendations are defined to provide assistance in CVD risk management in IJD, based on expert opinion and scientific evidence.

Tárgyszavak: Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Megjelenés: Annals Of The Rheumatic Diseases 76 : 1p.